Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. - Wikidata - awgldk - TriplyDB

Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.

Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.

http://www.wikidata.org/entity/Q33810788

about

Viscoelastic Methods of Blood Clotting Assessment - A Multidisciplinary Review CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media Point of care and factor concentrate-based coagulation algorithms An International Normalized Ratio-Based Definition of Acute Traumatic Coagulopathy Is Associated With Mortality, Venous Thromboembolism, and Multiple Organ Failure After Injury Applying results from clinical trials: tranexamic acid in trauma patients Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed.Taking the Blood Bank to the Field: The Design and Rationale of the Prehospital Air Medical Plasma (PAMPer) Trial Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays Trauma-Induced Coagulopathy: An Institution's 35 Year Perspective on Practice and Research.TEG®- or ROTEM®-based individualized goal-directed coagulation algorithms: don't wait--act now!Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage.Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid Polymorphisms on PAI-1 and ACE genes in association with fibrinolytic bleeding after on-pump cardiac surgery.Thromboelastography: A Practice Summary for Nurse Practitioners Treating Hemorrhage Design of the Study of Tranexamic Acid during Air Medical Prehospital Transport (STAAMP) Trial: Addressing the Knowledge Gaps.The "Death Diamond": Rapid thrombelastography identifies lethal hyperfibrinolysis.Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients.Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.Thromboelastographic Evaluation of Dogs with Acute Liver Disease Post-translational oxidative modification of fibrinogen is associated with coagulopathy after traumatic injury.Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.The challenge in management of hemorrhagic shock in trauma.State of the art: massive transfusion.Global assays of hemostasis.Management of traumatic haemorrhage--the European perspective.Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis.Hemoglobin-based oxygen carriers promote systemic hyperfibrinolysis that is both dependent and independent of plasmin.Management of Trauma-Induced Coagulopathy with Thrombelastography.Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion.Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage.Heterogeneous phase fibrinolysis rates by damped oscillation rheometry.Effect of solvent/detergent-treated pooled plasma on fibrinolysis in reconstituted whole blood.Decreasing the Use of Damage Control Laparotomy in Trauma: A Quality Improvement Project.[Uncritical use of tranexamic acid in trauma patients : Do no further harm!][Early viscoelasticity-based coagulation therapy for severely injured bleeding patients: Report of the consensus group on the consensus conference 2014 for formulation of S2k guidelines].

P2860

Q26781050-1D923995-9103-4622-89F8-78951A24EE4C Q26785966-182FF06C-98B2-40E5-9B0B-1A5958006BE7 Q27010188-74037104-52DF-4219-9232-ECE11359936D Q27318121-40334012-748F-4578-BFDD-A8399E0A87F0 Q28082587-888410D1-F93C-4EA6-B457-4640A450D1B2 Q30595449-871555FE-B9D2-4EEE-8EA4-A57455EA74EC Q31082543-26F1BE45-6205-47BB-A55C-928D7DCEA937 Q33457151-3DC7FE49-A72F-4B7E-8DE6-D2A533290B8F Q33676496-C739B06B-BC87-411B-8E64-5E0873F2267D Q33689210-BC2D8DDD-2F83-49B6-A198-3B0EC3DBC113 Q34429408-2D3BDC91-EA8C-4BBD-809A-9754A5C48C65 Q35091879-B14CD78F-71FF-485A-B2CC-E4E471356782 Q35207771-2D5127A8-C9A7-4C02-B62D-14BD1A9D3FDE Q35216740-E9853987-AC1D-4EB4-AA11-A9F8A0981997 Q35537165-F9F29C33-CBD7-4BFA-A6BA-0A4766F54194 Q35646892-3DB35A98-582B-43C7-9374-58DE86FBE14F Q35764909-24DCC4C4-64AD-41E7-B622-B58AE9C5E6E9 Q35926609-291E3763-EE89-45E7-9A1F-E423E545EA1A Q36215702-C7B2A04F-F2A1-4D95-8B28-4990423355E1 Q36387078-80B8062F-B1D4-4D36-8FF7-E58F4CDDD680 Q36396010-E7224E75-410E-45B9-B844-916980064525 Q36807586-6B0392EC-754E-4214-B0D6-823B258F728C Q36818081-8F3442D4-55A6-4899-B72E-465673B5655E Q36974769-67E802EE-5B08-46AB-827F-BA889DD7D336 Q37017207-2106B707-4D42-4A71-85F1-F93BC2169C64 Q37731832-5C6DE0E0-968A-40A6-AA61-7E49EBAB5F3C Q38213013-8AACF0D9-AC94-413E-9AAB-ECD23D040782 Q38217006-E4434B4C-8F0B-490C-871D-5832F3FE4DC3 Q38233155-0CE650CC-9655-4944-A429-D03889548B79 Q38273794-2EAC147E-F5E6-4A30-9224-CBB7C8DD3827 Q38653755-8CB40FD8-CE34-4FD7-AE6C-03F7FCF178C6 Q38732501-D97B1A99-F038-44A3-977D-B9FF90D6B2E4 Q39022502-BDEC5211-ADF9-41C7-B110-802581067FD3 Q39224083-C5C1DEA4-8784-4D9C-BD5D-60F72E42B413 Q39364102-99EA0BB7-204F-4D59-8E5B-E0518CA08C30 Q39545144-106093C5-64F2-4DC6-A904-BF5FAE49A99E Q40115273-8DED9E66-9D01-4FF9-ABD1-9D77965F5EC8 Q40236578-3DD36727-6C49-4CA7-A25B-857EF06EE678 Q40577604-C19F985B-0917-4701-A755-34D3EA66A555 Q41619894-CA2D682A-F685-468D-8CE6-D45A2FA5458F

P2860

Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.

http://www.wikidata.org/entity/Q33810788

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@ast

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@en

type

label

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@ast

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@en

prefLabel

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@ast

Fibrinolysis greater than 3% i ...... n of antifibrinolytic therapy.

@en

P1433

Q33810788-B67FAFD5-FC9C-4B90-865B-76275F45798B

P1476

Q33810788-019764D0-35DD-48CD-8D42-62569A94996A

P2093

Q33810788-329E9AC9-6C59-443A-933F-8B8B4ECB1732

Q33810788-5228DC14-181D-40F3-BB41-73AD9B59B0DC

Q33810788-65951B01-9561-4A46-AC2B-8F2E0E633237

Q33810788-67854D04-7F7C-4201-8C2E-651066749350

Q33810788-BB6FEE73-BC0D-4327-B224-15DAF16E0541

Q33810788-D989D9F5-50A4-4E11-9F6F-A583047D0624

Q33810788-DDB57033-F6EB-4F4F-9059-B5AFD5A4B78F

Q33810788-ECECAF24-4D32-472F-B8B0-412620C95DFB

P2860

Q33810788-0DB0DA57-5595-4D21-B028-2BEF25F7CB76

Q33810788-23BB3E52-873F-42AB-96C0-DA5CAAAE145F

Q33810788-24285C27-F60B-4375-9DB1-A90E88B7BAC2

Q33810788-28234C8C-D207-4781-8D70-BB29FC3EE616

Q33810788-29AEDE58-9BB7-4AFB-B4A7-86D9FC0FFC4A

Q33810788-2B39543A-421E-485D-B204-445C581EC9AE

Q33810788-3466354A-9A3A-4062-A537-514EC380845D

Q33810788-37BDF107-BF0D-4FED-8206-1417D943FF7E

Q33810788-42090D3F-0DF7-43C9-88C2-144354FF910B

Q33810788-514015C7-5284-46F1-850C-6A2A9BD05BD3

P304

Q33810788-D4BD42F1-86FE-43DC-8499-0F335E504565

P31

Q33810788-F48633FA-157B-417D-B18E-F4FE92A7803B

P356

Q33810788-EEBD1A27-3FE5-4804-A64B-2B8070041CF2

P433

Q33810788-B7251BF9-3681-4C34-810C-4564D5D08900

P478

Q33810788-3E96D6DA-EEC7-4DB3-B563-CDD9F23B7AEA

P50

Q33810788-08CE3E16-5791-4085-BA9E-8818EED144F9

Q33810788-7A58B043-EE31-4ACD-9BDC-01BD5AB759A6

P577

Q33810788-E35B8308-F3ED-49CF-8527-599C359D3767

P698

Q33810788-E467B910-E176-4DA4-82B6-0E567CDAE572

P932

Q33810788-07A71BA3-5135-4FED-81CA-135E6705F110

P356

TA.0B013E3182AA9C9F

P1433

The Journal of Trauma and Acute Care Surgery

P1476

Fibrinolysis greater than 3% i ...... on of antifibrinolytic therapy

@en

P2093

Angela Sauaia

http://www.w3.org/2001/XMLSchema#string

Arsen Ghasabyan

http://www.w3.org/2001/XMLSchema#string

Christopher C Silliman

http://www.w3.org/2001/XMLSchema#string

Christopher R Ramos

http://www.w3.org/2001/XMLSchema#string

Ernest E Moore

http://www.w3.org/2001/XMLSchema#string

John R Stringham

http://www.w3.org/2001/XMLSchema#string

Michael P Chapman

http://www.w3.org/2001/XMLSchema#string

Theresa L Chin

http://www.w3.org/2001/XMLSchema#string

P2860

Early and individualized goal-directed therapy for trauma-induced coagulopathy

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial

Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial

Criteria for empiric treatment of hyperfibrinolysis after trauma.

Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding?

Treating coagulopathy in trauma patients.

Crystalloid to packed red blood cell transfusion ratio in the massively transfused patient: when a little goes a long way.

Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy.

Acute coagulopathy of trauma: mechanism, identification and effect.

Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography.

P304

961-7; discussion 967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TA.0B013E3182AA9C9F

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Anirban Banerjee

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24256667

http://www.w3.org/2001/XMLSchema#string

P932

4072127

http://www.w3.org/2001/XMLSchema#string